Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease - Université de Lorraine Access content directly
Journal Articles Journal of Crohn's and Colitis Year : 2016

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

Abstract

Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity. We included patients with endoscopic signs of inflammation after anti-CTLA-4 infusions for cancer treatment. Other causes of enterocolitis were excluded. Clinical, biological and endoscopic data were recorded. A single pathologist reviewed endoscopic biopsies and colectomy specimens from 27 patients. Patients with and without enterocolitis after ipilimumab-treated melanoma were compared, to identify clinical factors associated with enterocolitis. Thirty-nine patients with anti-CTLA-4 enterocolitis were included (ipilimumab

Dates and versions

hal-01659102 , version 1 (08-12-2017)

Identifiers

Cite

L. Marthey, C. Mateus, C. Mussini, M. Nachury, S. Nancey, et al.. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10 (4), pp.395-401. ⟨10.1093/ecco-jcc/jjv227⟩. ⟨hal-01659102⟩
100 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More